Encorafenib FoundationOne liquid companion diagnostic - Foundation Medicine
Alternative Names: FoundationOne®Liquid CDx - Foundation MedicineLatest Information Update: 05 Dec 2023
At a glance
- Originator Foundation Medicine
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Colorectal cancer; Non-small cell lung cancer
Most Recent Events
- 15 Nov 2023 Foundation Medicine and Pierre Fabre agree to develop encorafenib FoundationOne companion diagnostic for Non small cell lung cancer in European Union
- 11 Oct 2023 Registered for Non-small cell lung cancer (Diagnosis) in USA (unspecified route)
- 09 Jun 2023 Registered for Colorectal cancer (Diagnosis) in USA (unspecified route)